Acadia Pharmaceuticals price target raised to $37 from $32 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $37 from $32 and keeps a Buy rating on the shares following the approval of Daybue Stix. The approval unlocks access for patients who previously couldn’t swallow the large liquid volumes, the analyst tells investors in a research note. The firm’s key opinion leader analysis suggests the powder formulation could reduce stomach issues by removing specific additives, while solving the taste struggles that cause families to stop treatment.